Akari Therapeutics (AKTX) Return on Capital Employed (2015 - 2026)

Akari Therapeutics has disclosed Return on Capital Employed across 5 years of filings, most recently posting 107.4% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 107.4%, up 31429.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 107.4% (up 31429.0% YoY), and the FY2025 annual result was 46.85%, up 23987.0% from the prior year.
• Return on Capital Employed came in at 107.4% for Q1 2026 at Akari Therapeutics, down from 50.39% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 659.1% in Q1 2024 to a low of 1904.88% in Q4 2024.
• The 3-year median for Return on Capital Employed is 107.4% (2026), against an average of 194.45%.
• Peak annual rise in Return on Capital Employed reached 185449 bps in 2025, while the deepest fall reached 108078 bps in 2025.
• Akari Therapeutics' Return on Capital Employed stood at 1904.88% in 2024, then jumped by 97 bps to 50.39% in 2025, then sank by 113 bps to 107.4% in 2026.
• The last three Return on Capital Employed figures came in at 107.4% (Q1 2026), 50.39% (Q4 2025), and 386.9% (Q3 2025), per Business Quant data.